The video is now on Galena's Facebook page. Very positive interview.
Hey stock I don't get your point. women have to be free of cancer after going through SOC treatments to get into the PRESENT trial. NeuVax is for recurring cancer. NeuVax is the only immuno in ph 3 trials. It doesn't matter how great SOC is or detection for that matter. Women are recurring at about a 23% average.
Then bash with correct info!
Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax™ (nelipepimut-S)
Issued Patent Will Cover Multiple Additional Claims Around the Use of NeuVax
SAN RAMON, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax™ (nelipepimut-S). NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.
The patent will cover the use of NeuVax for the following indications:
Inducing and maintaining an immune response to HER2 expressing tumor cells in patients in clinical remission with a tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 (FISH
Xtra, I feel the same as you. I bought in April 2012 knowing well that I would probably have to wait till Q1 of 2018 for the fiinal readout of NeuVax data. If something happens that NeuVax fails or GALE gets a partner or buyout, so be it. I've been down this road many times before.
Yes eye4 this has happened a few times before for GALE at the end of the month. Once it happened to three bios I held at the same time.
After doing a search for "data mining in biotech" there are many companies using this technique in their drug trials
Lilly's data mining may pay off with nearly-abandoned Alzheimer's drug
By Nicole Gray | June 29, 2015
In 2012, researchers at Eli Lilly were ready to give up on solanezumab, an experimental drug for Alzheimer's disease (AD), but after combing through reams and reams of clinical data, results from two studies changed their minds.
Pfizer Data Mining Focuses on Clinical Trials
Pfizer is stepping up its efforts to get more information from existing clinical trial data. The company is turning to sophisticated data mining techniques to help improve the design of new trials, to better understand possible new uses for existing drugs, and to help examine how drugs are being used after they have been approved.
“We want to milk as much out of the data as possible,” says Mani Lakshminarayanan, director/statistical scientist, at Pfizer.
Data Mining in Drug Development and Translational Medicine
Author: Hermann Mucke, PhD
The biopharmaceutical industry is grappling not only with sheer data volume but with the ability of researchers to extract information through identification and contextual analysis of those data that are relevant to a particular set of investigations. This report examines:
Techniques, technology, and software used in life science data mining
Data mining for early preclinical safety assessments
Data mining in clinical trials
Data mining in pharmacovigilance
Business models and solutions in drug development bioinformatics
The mountain of data generated and stored is growing ever-higher. The information content of life science data is multidimensional and not readily accessible by merely looking at the output. Unless such data can be put into proper context and interpreted—i.e., mined—their value is only in their potential. Data Mining in Drug Development and Translational Medicine examines data mining challenges and approaches in pharmaceutical R&D.
The pharmaceutical industry has made decisive moves to improve the predictiveness of early-stage drug safety testing. These efforts generate large amounts of data, in which the clue to safety-related, potential “red flags” can be buried. In this context we examine options for mining types of text data, “pathway mining” for pathway-related effects of a compound, and the multidimensional output of high-content screening methods. Also examined are approaches to mining data generated in preclinical trials for identification of toxicity signatures.
Hey screen, GALE has this posted on their web site now. It is a 13G Schedule with a rule 13d-1.Seems as though Blackrock has increased its holdings of GALE.
Hey screen I saw this also. I think Zacks has a few newbies writing for them now, they can't make up their mind. Upgrade, downgrade, upgrade and downgrade!
Excerpt from his Motley Fool piece
Research into halting cancer recurrence is still a relatively new concept. However, one therapy in development worth eyeing is Galena Biopharma's NeuVax. Currently in late-stage studies, NeuVax is an immune-boosting injection that's administered 11 times over three years and designed to prevent low-to-moderate HER2-expressing breast cancer recurrence. Midstage studies showed a 78% reduction relative to the placebo in recurrence rates. Galena is also working on a similar therapy to block endometrial and ovarian cancer recurrence for women.
For investors, cancer research appears as if it'll remain an area of high potential growth. But more importantly, cancer patients can hopefully look forward to more directed and personalized cancer treatment in the coming years, which may translate into improved survival and quality of life.
Kramer, back in April 2012 I got together 34 individuals mostly in the medical field to invest in GALE. I've been retired for over ten years but do consulting work part time at 5 different hospitals in the Midwest and Northeast. After 3 1/2 years we now have 62 people( mostly professionals in the medical field) invested in GALE. We own a very substantial amount of shares which none of us have sold. At last count only 17 have registered at Dan's website. I know for a fact there are other pools out there that own large blocks also. If the people who have shorted have inflated the share count on his site, what good would it do them? It may backfire on them. I don't understand your logic.
Also OPS, Mark gave a very professional presentation. He might be getting nudged to get his and Galena's act together from an outside source. Could a partner be in the works? Anything is possible.